The Hong Kong United Cancer Centre is currently conducting several international clinical studies. If you are:
- Newly diagnosed patients with lung cancer
- Newly diagnosed patients with localized small cell lung cancer
- Patients with diffuse non-small cell lung cancer who have received chemotherapy and chemotherapy-free treatment (and the tumor is known to have no mutations in the EGFR and ALK genes)
- Lung cancer patients with specific gene mutations: KRAS G12C, ROS1, HER2, MET
- Any cancer patient with a specific gene mutation: NTRK
- Patients with non-diffuse breast cancer who are receiving postoperative adjuvant hormone therapy
- Patients with diffuse breast cancer who are being treated with hormones and CDK4/6 inhibitors
- Patients with gastrointestinal stromal cell tumors who have received targeted therapy
- Patients with low HER2 expression and hormone receptor-positive metastatic breast cancer who have disease progression after endocrine therapy
Please call our cancer center as soon as possible for further follow-up. Those interested can contact us through the following methods
Whatsapp：5518 2992 Email: Enquiry@hkuoc.hk
If you initially meet the enrollment criteria, the center will provide free one-on-one consultation services with an oncology specialist.
What is clinical research?
Ongoing research - Recruiting Clinical Trials
Completed research drugs - Completed Clinical Trial
Ongoing
Lung cancer
A clinical study recruiting patients with stage I non-small cell lung cancer who have completed tumor resection surgery, are ctDNA positive, or have high-risk pathological features
completed
Lung cancer
EGFR/ HER2
Clinical studies recruiting patients with advanced non-small cell lung cancer (NSCLC) with EGFR and/or HER2 mutations
completed
Lung cancer
α (FOLR1)
Clinical studies recruiting patients with advanced or metastatic non-small cell lung cancer who have previously received treatment and expressed folic acid receptor alpha (FOLR1)
Ongoing
Lung cancer
HER2
Recruit patients with non-resectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) with mutations in HER2 exon 19 or 20 to participate in clinical studies of the research drug Trastuzumab Deruxtecan.
completed
Metastatic gastrointestinal stromal tumor
Recruit patients with metastatic gastrointestinal stromal tumors with locally advanced stages that cannot be surgically removed, imatinib resistance or intolerance to participate in the clinical research of the research drugs CGT9486 (formerly PLX9486) and sunitinib.
completed
breast cancer
HER2-
Patients with HR+ and HER2-advanced breast cancer with PIK3CA mutations were recruited to receive Alpelisib (BYL719) clinical research drugs.
completed
Diffuse large B-cell lymphoma
Recruit newly diagnosed patients with diffuse large B-cell lymphoma to participate in the clinical research of Tafasitamab research drugs.
completed
Lung cancer
KRAS G12C
Recruit patients with KRAS G12C mutant non-small cell lung cancer who have received treatment to participate in the clinical study of Adagrasib (MRTX849) research drug.
completed
ESCC
PD-1
Patients with advanced esophageal squamous epithelial cell carcinoma were recruited to participate in the clinical study of Pembrolizumab (MK-3475) research drug.
completed
Lung cancer
PD-1
Recruit patients with metastatic non-small cell lung cancer and patients who have not yet started treatment to participate in the clinical research of the research drugs Zimberelimab and domvanalimab.
Ongoing
Lung cancer
Study Item: NCT06818784: RASolve 301 Study
Ongoing
Lung cancer
The Hong Kong Joint Cancer Centre is now recruiting patients with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression to participate in the phase 1b/2 clinical study NCT06162572
Ongoing
breast cancer
The Hong Kong Joint Oncology Centre is now recruiting triple negative breast cancer (TNBC) patients to participate in the Phase 3 clinical study NCT06393374. For those who have not achieved pathological complete response (pCR), MK-2870 combined with Pembrolizumab treatment will be used, with free medication and imaging scanning fees. Get in touch with us immediately to inquire about eligibility, research process, and risks.
Ongoing
Lung cancer
The Hong Kong Joint Oncology Centre is now recruiting patients with resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) to participate in the Phase 3 clinical study NCT06312137, using Pembrolizumab combined with MK-2870 treatment, with free medication and imaging scanning fees. Get in touch with us immediately to inquire about eligibility, research process, and risks.
Ongoing
Lung cancer
HER2
The United Cancer Centre of Hong Kong is now recruiting patients with advanced non-small cell lung cancer (NSCLC) with HER2 gene mutations to participate in the phase 3 clinical study NCT06452277, using BAY 2927088
Ongoing
breast cancer
HER2
The United Cancer Centre of Hong Kong is now recruiting patients with low HER2 expression and hormone receptor-positive metastatic breast cancer to participate in the phase 3 clinical study NCT06018337, using DB-1303 or chemotherapy regimen, drugs and image scans are free of charge. To understand the eligibility for application, the research process and the risks, please contact us immediately for details.
Ongoing
breast cancer
ER+/HER2
Recruit patients with ER+, HER2-advanced or metastatic breast cancer after treatment with endocrine and CDK4/6 inhibitors to participate in the clinical study of the research drug OP-1250 (Palazestrant).
Completed research drugs - Completed Clinical Trial
Ongoing
Lung cancer
A clinical study recruiting patients with stage I non-small cell lung cancer who have completed tumor resection surgery, are ctDNA positive, or have high-risk pathological features
completed
Lung cancer
EGFR/ HER2
Clinical studies recruiting patients with advanced non-small cell lung cancer (NSCLC) with EGFR and/or HER2 mutations
completed
Lung cancer
α (FOLR1)
Clinical studies recruiting patients with advanced or metastatic non-small cell lung cancer who have previously received treatment and expressed folic acid receptor alpha (FOLR1)
Ongoing
Lung cancer
HER2
Recruit patients with non-resectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) with mutations in HER2 exon 19 or 20 to participate in clinical studies of the research drug Trastuzumab Deruxtecan.
completed
Diffuse large B-cell lymphoma
Recruit newly diagnosed patients with diffuse large B-cell lymphoma to participate in the clinical research of Tafasitamab research drugs.
completed
Lung cancer
KRAS G12C
Recruit patients with KRAS G12C mutant non-small cell lung cancer who have received treatment to participate in the clinical study of Adagrasib (MRTX849) research drug.
completed
ESCC
PD-1
Patients with advanced esophageal squamous epithelial cell carcinoma were recruited to participate in the clinical study of Pembrolizumab (MK-3475) research drug.
completed
Lung cancer
PD-1
Recruit patients with metastatic non-small cell lung cancer and patients who have not yet started treatment to participate in the clinical research of the research drugs Zimberelimab and domvanalimab.
completed
colorectal cancer
Recruit patients with advanced inoperable metastatic colorectal cancer who have received treatment to participate in clinical studies of Magrolimab, Bevacizumab and FOLFIRI research drugs.
The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced/metastatic breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the eligibility criteria for this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.
The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical study. If you are at high risk of early triple negative breast cancer (TNBC)
completed
breast cancer
HER2-
Patients with HR+ and HER2-advanced breast cancer with PIK3CA mutations were recruited to receive Alpelisib (BYL719) clinical research drugs.
completed
breast cancer
PD-L1
Recruit untreated patients with locally advanced inoperable or metastatic PD-L1-positive triple-negative breast cancer who have not received treatment to participate in clinical studies of Sacituzumab Govitecan (Trodelvy®) and Pembrolizumab investigational drugs.
completed
breast cancer
HER2
Recruit patients with metastatic triple-negative breast cancer who have not received treatment to receive Magrolimab clinical research drugs
completed
breast cancer
HER2
Recruit patients with drug-resistant or refractory HER2-positive metastatic breast cancer with T-DM1, T-DxD, or Tucatinib